

# 1 Publication bias in pharmacogenetics of statin- 2 associated muscle symptoms, an umbrella review 3 with a meta-epidemiological study

4  
5 A Gougeon, MSc <sup>1,2</sup>, I Aribi, MSc <sup>1</sup>, S Guernouche, MSc <sup>3</sup>, JC Lega, MD-PhD <sup>1,4,5</sup>, JM  
6 Wright, MD-PhD <sup>6</sup>, C Verstuyft PharmD-PhD <sup>7</sup> A Lajoinie, PharmD-PhD<sup>2</sup>, F Gueyffier, MD-  
7 PhD <sup>1</sup>, G Grenet, MD-PhD <sup>1,5</sup>

8 <sup>1</sup> Laboratoire de Biométrie et Biologie Evolutive UMR CNRS 5558, Université Lyon 1, Université de  
9 Lyon, Villeurbanne, France

10 <sup>2</sup> RCTs, Lyon, France

11 <sup>3</sup> Service de neurochirurgie pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon,  
12 France

13 <sup>4</sup> Service de Rhumatologie, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France

14 <sup>5</sup> Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle Santé Publique, Hospices Civils de  
15 Lyon, Lyon, France

16 <sup>6</sup> Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia,  
17 Vancouver, BC, Canada

18 <sup>7</sup> Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux  
19 Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin  
20 Bicêtre, F-94275, France

21

22

23

24

## 25 **Corresponding author:**

26 Arthur Gougeon

27 Laboratoire de biométrie et biologie évolutive – UMR 5558, Université Lyon 1 site Laennec,

28 7 rue Guillaume Paradin, Bât B 69008 LYON

29 Tel : + 33 4.78.78.57.55

30 E-mail : [arthur.gougeon@etu.univ-lyon1.fr](mailto:arthur.gougeon@etu.univ-lyon1.fr)

31 Abstract (345 words / 350)

32

33 ***Background:***

34 Statin-associated muscle symptoms (SAMS) are a major cause of treatment discontinuation.  
35 Adjusting statin dosages for solute carrier organic anion transporter family member 1B1  
36 (SLCO1B1) genotype has been proposed to reduce SAMS. We hypothesized that the  
37 association between SLCO1B1 genotype and SAMS is misestimated because of publication  
38 bias.

39 ***Methods:***

40 We searched for published systematic reviews evaluating the association between SLCO1B1  
41 genotype and SAMS. We collected the odds ratio (OR) of this association in each clinical study.  
42 We assessed the presence of publication bias using the visual inspection of a funnel plot and  
43 Egger's test and used the Bayes Factor ( $BF_{\text{Publication-bias}}$ ) of the Robust Bayesian Meta-Analysis  
44 (RoBMA) as a sensitivity analysis. We evaluated the effect of publication bias by comparing  
45 qualitatively and quantitatively (ratio of OR [ROR]) OR of the meta-analysis i) uncorrected for  
46 potential publication bias ( $OR_{\text{Uncorrected}}$ ) and ii) corrected using the trim-and-fill ( $OR_{\text{Trim\&Fill}}$ ).  
47 We also used the RoBMA ( $OR_{\text{RoBMA}}$ ) for corrected OR as a sensitivity analysis. Our primary  
48 analysis covered the associations between any SLCO1B1 genotype and any statin drug.  
49 Secondary analysis focused on SLCO1B1 genotypes and statin drug subgroups.

50 ***Results:***

51 We included 8 cohort and 11 case-control studies, totaling 62 OR of three SLCO1B1 genotypes  
52 and five statin drugs plus one 'mixed' statin treatment. All controls were statin-tolerant patients.  
53 In the primary analysis, the funnel plot was suggestive of publication bias, confirmed by  
54 Egger's test ( $p=0.001$ ) and RoBMA ( $BF_{\text{Publication-bias}}=18$ ). Correcting the estimate for publication

55 bias resulted in loss of the association, from a significant  $OR_{Uncorrected}$  (1.31 95% CI [1.13–  
56 1.53]) to corrected ORs suggesting no difference: i)  $OR_{Trim\&Fill}$  (1.07 95% CI [0.89–1.30]) and  
57 ii)  $OR_{RoBMA}$  (1.02 95% CI [1.00–1.33]). The  $ROR_{Trim\&Fill}$  and the  $ROR_{RoBMA}$  suggested that  
58 publication bias overestimated the association by 18% and 23%, respectively. The results were  
59 similar for the most studied SLCO1B1 genotype, as for simvastatin and atorvastatin.

60 ***Conclusion:***

61 The effect of the SLCO1B1 genotype on the risk of developing SAMS is overestimated in the  
62 published literature. This could lead prescribers to incorrectly decreasing statin doses or even  
63 avoiding statin use, leading to a loss of the potential cardiovascular benefit of statins.

64 **Key words: Statin, SAMS, Myopathy, Adverse event, SLCO1B1, Pharmacogenetic,**  
65 **Publication bias, Umbrella review, Meta-analysis, RoBMA**

66

67 **Clinical perspective**

68 **What is new?**

- 69       • There is significant publication bias in the available literature regarding the association  
70       between SLCO1B1 genotype and statin-associated muscle symptoms.
- 71       • The available literature overestimates the importance of the SLCO1B1 genotype on  
72       statin-associated muscle symptoms.

73 **What are the clinical implications?**

- 74       • The cardiovascular benefit of statins might be wrongly lost when adjusting statin  
75       therapy with the SLCO1B1 genotype.
- 76       • The effect of publication bias should be considered when writing guidelines.

77

## 78 Non-standard Abbreviations and Acronyms

79

80 LDL-C : Low-density lipoprotein cholesterol

81 RCT : Randomized controlled trial

82 CV : Cardiovascular

83 AE : Adverse event

84 SAMS : Statin-associated muscle symptoms

85 CK : Creatine kinase

86 SLCO1B1 : Solute carrier organic anion transporter family member 1B1

87 EMA : European Medicines Agency

88 FDA : Food and Drug Administration

89 CPIC : Clinical Pharmacogenetics Implementation Consortium

90 T&F : Trim-and-Fill

91 NOS : Newcastle-Ottawa scale

92 SNP : Single nucleotide polymorphism

93 PRISMA : Preferred Reporting Items for Systematic Reviews and Meta-Analyses

94 OR : Odds ratio

95 CI : Confidence interval

96  $OR_{\text{Trim\&Fill}}$  : OR corrected for publication bias by Trim and Fill method

97  $ROR_{\text{Trim\&Fill}}$  : Ratio of odds ratio ( OR corrected by Trim and Fill method)

98  $OR_{\text{Uncorrected}}$  : OR uncorrected for publication bias

99 RoBMA : Robust Bayesian Meta-Analysis

100 BF : Bayes factor

101  $OR_{\text{RoBMA}}$  : OR corrected for publication bias by RoBMA approach

102  $ROR_{\text{RoBMA}}$  : Ratio of odds ratio ( OR corrected by RoBMA approach)

103 SNP : Single Nucleotide Polymorphism

104 WT : Wild type

105

## 106 INTRODUCTION

107 Statins decrease low-density lipoprotein cholesterol (LDL-C). Several randomized controlled  
108 trials (RCTs) have confirmed the cardiovascular (CV) benefits of several statins in different  
109 primary and secondary prevention populations [1–3]. The most common reported adverse  
110 events (AEs) are statin-associated muscle symptoms (SAMS). SAMS range from myalgia to  
111 rhabdomyolysis, with or without elevated creatine kinase (CK); they decrease or stop after  
112 treatment discontinuation [4]. The exact mechanism of statin muscle toxicity has yet to be fully  
113 clarified [5]. SAMS occurrence is likely to limit patient adherence to statins. The prevalence of  
114 muscle symptoms in treated patients has been estimated to be around 10% [range 5%–25%].  
115 More specifically, muscular symptoms only attributable to statins have been estimated around  
116 1-2% [ranging from 0.5% to 4%] [4]. Several genotypes of the solute carrier organic anion  
117 transporter family member 1B1 (SLCO1B1) gene have been reported to be associated with an  
118 increased risk of SAMS [6–11]. The SLCO1B1 gene encodes for the OATP1B1 protein, which  
119 is involved in the hepatic transport of statins. The European Medicines Agency (EMA) and the  
120 Food and Drug Administration (FDA) have listed the SLCO1B1 gene mutation as a potential  
121 marker for SAMS. The Clinical Pharmacogenetics Implementation Consortium (CPIC)  
122 recently updated their guidelines and recommend dose adjustment for statin treatment  
123 according to SLCO1B1 genotype “if pharmacogenetic test results are available” to reduce the  
124 risk of SAMS [12]. The impact of genetic information on prescription changes according to  
125 CPIC guidelines was evaluated in a recent study [13]. In 64% of cases, decision aids were used  
126 by prescribers, resulting in: a reduced dose of simvastatin in 74% and change in the statin in  
127 26%. Although CPIC does not endorse genetic testing to determine the SLCO1B1 genotype,  
128 their estimates suggest that 11-36% of individuals have an intermediate activity phenotype and  
129 0-6% have a low activity phenotype [12].

130 However, the supposed association between SAMS and SLCO1B1 genotype might be affected  
131 by publication bias [14]. Such publication bias has been documented in drug safety assessment  
132 [15], genetic epidemiology [16] and more recently in pharmacogenetics [17]. Regarding the  
133 SLCO1B1—SAMS association, the available systematic reviews suggest a potential significant  
134 publication bias but failed to take it into account. The meta-analysis of Jiang *et al.* reported a  
135 significant association between a SLCO1B1 genotype and an increased risk of AE for various  
136 statins [18]. However, they also reported significant Egger's and Begg's tests for one  
137 association, but without including this particular risk of bias in their conclusion or in the  
138 abstract. Moreover, they acknowledged in the discussion section that their review might lack  
139 power to detect publication bias. More recently, Xiang *et al.* reported a significant increased  
140 risk of SAMS with specific SLCO1B1 genotype [19]. However, among the eight Egger's and  
141 Begg's tests they reported, four were significant (p value <5%). Moreover, they used the trim-  
142 and-fill (T&F) correction to take into account the publication bias, and reported a loss of the  
143 association for one out the three reported corrected ORs [20]. However, they did not state this  
144 publication bias and its impact in the conclusion or in the abstract. The presence of this  
145 uncertainty poses a significant concern, considering the fact that guidelines are recommending  
146 the use of SLCO1B1 genotype to reduce the incidence of SAMS [12]. Consequently, accurately  
147 estimating the association between the SLCO1B1 genotype and SAMS is imperative for making  
148 well-informed clinical decisions.

149 Therefore, we aimed to systematically assess the presence and the effect of publication bias on  
150 the association between SLCO1B1 genotype and SAMS.

151 **METHODS**

152 *Protocol and registration*

153 The protocol was registered *a priori* on the Open Science Framework (OSF) website:  
154 <https://osf.io/36jq8/>. Our methodology complied with the Cochrane Handbook for Systematic  
155 Reviews of Interventions [21]. We reported our study in accordance with the Preferred  
156 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist  
157 (Supplemental material [S1]) [22]. The current study follows the methodology already used in  
158 a similar work we previously published [17].

159 *Search strategy and inclusion criteria*

160 We conducted an umbrella review of the literature up to November 2022. We used PubMed,  
161 Embase and Cochrane Central. Our search terms were: "[polymorphism genetic OR solute  
162 carrier organic anion transporter 1B1 OR SLCO1B1 OR organic anion transporter polypeptide  
163 1B1 OR OATP1B1] AND [statin OR rosuvastatin OR fluvastatin OR pravastatin OR  
164 simvastatin OR cerivastatin OR lovastatin OR atorvastatin OR pitavastatin] AND [myopathy  
165 OR myalgia OR myositis OR rhabdomyolysis OR creatine kinase OR CK]" (see S2 for details).  
166 We restricted the search to articles published in English. In addition, we performed a manual  
167 search in the references of articles obtained by the automatic search. Three reviewers (AG, IA,  
168 SG) independently selected the articles based on title and abstract then on full text. Any  
169 disagreement over article selection was resolved by consensus. Our PICOt criteria were as  
170 follow: (i) patient: humans, (ii) intervention: any statin, (iii) comparator: any control, (iv)  
171 outcome: point estimate of SLCO1B1-SAMS association, (v) type of publication: systematic  
172 reviews and meta-analyses. Our inclusion criteria were: (i) systematic reviews published in  
173 peer-reviewed journals [23], (ii) examining the association between SLCO1B1 genotype and  
174 SAMS, (iii) including clinical studies, (iv) published in English, and (v) calculation of point  
175 estimate using meta-analyses. We focused on English-published studies as they are more likely  
176 to be used in guidelines. Indeed, the CPIC guideline on the topic was restricted to English



177 articles for the SLCO1B1 assessment [12]. In this way, our results are representative of the  
178 literature that is used for such guideline elaboration.

### 179 *Data extraction and quality assessment of included studies*

180 Two independent reviewers (AG, IA) extracted the data using a standardized form. Extracted  
181 data included study characteristics (e.g. authors, year of publication), information on the statins  
182 studied (e.g. type, dose), genetic variants of the SLCO1B1 gene, muscle pain criteria, measures  
183 of association—odds ratios (OR) and confidence intervals (CI), and adjustments for potential  
184 covariates. When some data of a clinical study were missing in the included systematic reviews,  
185 we extracted them from the original clinical study report. The risk of bias in the clinical studies  
186 was the one provided by the included systematic review, following the Cochrane Handbook  
187 recommendations for umbrella review [21].

### 188 *Dataset*

189 Our dataset included all point estimates as OR and its 95% CI of the association between SAMS  
190 and SLCO1B1 genotype collected across the included systematic reviews. Clinical studies  
191 included in more than one systematic review were used only once (S3). The dataset also  
192 included characteristics associated with the point estimates: type of statin, type of  
193 polymorphism and genetic model (homozygous comparison, heterozygous comparison,  
194 dominant, allelic) used for subgroup analyses.

### 195 *Primary, secondary and exploratory analyses*

196 Our primary analysis integrated all point estimates: any SLCO1B1 single nucleotide  
197 Polymorphism (SNPs), any statin. In the primary analysis, we prioritized the homozygous (CC  
198 vs TT) and heterozygous (TC vs TT) comparisons to avoid overlapping measurements for the  
199 same clinical study.

200 Our secondary analysis assessed publication bias in different subgroups: each SLCO1B1 SNP,  
201 focus each statin type and each genetic model (heterozygous comparison, homozygous

202 comparison, allelic model - C vs T - or dominant model - TC + CC vs TT - ) when possible ( $\geq$   
203 10 point estimates needed for Egger's test) [24]. We also performed an analysis focused on SNP  
204 rs4149056 because it is the most incriminating SNP in SAMS.

205 We also conducted exploratory analyses to look for a source of publication bias according to  
206 three factors: clinical study sponsors, statin drug names, and ethnic groups. For these three  
207 potential sources, we plotted the main funnel plot but distinguishing private versus public  
208 sponsors for the first one, statin drug names for the second one, and according to the ethnic  
209 groups as reported in the included systematic reviews for the third one, although the reporting  
210 of population differences in clinical research is inconsistent and plagued with methodological  
211 issues [25].

### 212 *Statistical analysis*

213 We first used the funnel plot to assess the presence of publication bias. Two independent  
214 researchers (AG, IA) visually analyzed the funnel plots and classified them as: "suggestive of  
215 a publication bias", "not suggestive of a publication bias", or "not assessable". Agreement was  
216 estimated using Free-marginal kappa estimator [26]. A third researcher (GG), blinded to the  
217 previous classifications, helped resolve disagreements. Second, we used Egger's test for  
218 associations with at least 10 point estimates [24]. We did not use Begg's test [27]. When the  
219 Egger's test was significant, we added a sensitivity analysis using the Robust Bayesian Meta-  
220 Analysis (RoBMA) approach (see "sensitivity analysis" section) [28].

221 We estimated the SLCO1B1-SAMS association at the meta-analysis level i) without and ii) with  
222 a correction for publication bias. We used an inverse variance weighting random-effect meta-  
223 analysis to estimate the uncorrected OR ( $OR_{Uncorrected}$ ) and its 95% confidence interval (95%  
224 CI). Inter-study heterogeneity was assessed using the Cochran's Q test, with significance set at  
225  $p < 0.05$ , and the  $I^2$  was calculated [29]. When publication bias was confirmed by a significant  
226 p-value of the Egger's test, we estimated a corrected OR ( $OR_{Trim\&Fill}$ ) and its 95% CI, using the

227 T&F method [20]. We then compared the estimate of the SLCO1B1-SAMS association i)  
228 qualitatively (significant or not significant association) and ii) quantitatively by calculating the  
229 ratio of the OR ( $OR_{\text{Trim\&Fill}} / OR_{\text{Uncorrected}}$ ) and its 95% CI ( $ROR_{\text{Trim\&Fill}}$ ) (see for details S4).

### 230 *Sensitivity analysis*

231 We conducted sensitivity analyses using the recently proposed Robust Bayesian Meta-Analysis  
232 (RoBMA) approach [28]. RoBMA integrates several publication bias detection and correction  
233 methods, notably selection models that are less sensitive to heterogeneity [30]. RoBMA results  
234 use Bayes factors (BF), a continuous measure of evidence in favor of the presence or absence  
235 of effect, heterogeneity and publication bias. Bayes factor values above 10 indicate very strong  
236 evidence, from 3 to 10 moderate evidence, and from 1 to 3 weak evidence. In several simulation  
237 studies, RoBMA was found to be superior to other bias correction methods [28]. RoBMA has  
238 been used notably in the field of psychology [31–33]. We used RoBMA to provide a sensitivity  
239 analysis of i) the publication bias detection, when the Egger’s test was significant and ii) the  
240 evaluation of the publication bias effect, by providing a corrected  $OR_{\text{RoBMA}}$  and comparing it to  
241 the  $OR_{\text{Uncorrected}}$  as previously described with the T&F method. The ratio  $OR_{\text{RoBMA}}$  divided by  
242  $OR_{\text{Uncorrected}}$  being  $ROR_{\text{RoBMA}}$ .

243 We conducted the analyses using the R 4.2.2 software [34] and the package meta (6.2-1) [35]  
244 and RoBMA (2.3.1). All p-values were considered significant at 0.05 without multiple testing  
245 adjustment.

246

## 247 RESULTS

### 248 *Study selection and characteristics*

249 Out of 436 identified references, we included 6 systematic reviews, totaling 19 original clinical  
250 studies, from which we extracted 62 unique point estimates of the association between the  
251 SLCO1B1 genotype and SAMS (Figure 1).

252 All clinical studies used wild-type (WT) statin-tolerant patients as a control group, leading to  
253 an observational design for the assessment of this association for all studies (losing the benefit  
254 of randomization when they were part of a randomized trial). They evaluated one or more  
255 statins, mainly simvastatin and atorvastatin; 6 did not specify the statin drugs (statin mixed).  
256 Eighteen clinical studies evaluated rs4149056 single nucleotide polymorphisms (SNPs), 7  
257 evaluated rs2306283 and 3 evaluated rs4363657 of the SLCO1B1 gene (Table 1). The criteria  
258 for assessing myopathy varied between studies, with the main criterion being muscle symptoms,  
259 irrespective of elevated CK levels. However, the reporting of the muscle adverse event was  
260 highly heterogeneous, precluding any subgroup constitution. The study population was  
261 predominantly of European descent. One clinical study was sponsored by a pharmaceutical  
262 company.

263 The risk of bias of the clinical studies was assessed using the Newcastle-Ottawa Scale (NOS)  
264 in 5 reviews and the Risk of Bias Score for Genetic Association Studies in 1 review (i.e.  
265 Turongkaravee, 2021). The overall risk of bias was low as all the point estimates of the  
266 SLCO1B1-SAMS associations were assessed using non-randomized comparisons (for details  
267 see S3,S5).

### 268 *Primary analysis*

#### 269 *Detection of the presence of publication bias*

270 We included 62 point estimates in the primary analysis. The visual inspection of the funnel plots  
271 was suggestive of publication bias (kappa agreement between the two reviewers: 64%). The

272 visual inspection also revealed a possible clustering of the estimates around the significant p-  
273 value thresholds (Figure 2). The asymmetry was confirmed by Egger's test ( $p=0.001$ ) (Table  
274 2). The sensitivity analysis with RoBMA showed strong evidence for publication bias with a  
275  $BF_{\text{Publication-bias}}$  of 18 (Table 2, S6).

#### 276 *Evaluation of the impact of publication bias on the association estimate*

277 The uncorrected meta-analysis yielded an estimate with a 31% significant increased risk of  
278 SAMS with SLCO1B1 genotype ( $OR_{\text{Uncorrected}} = 1.31$  CI 95% 1.13–1.53), with substantial  
279 heterogeneity (Cochran's Q test  $p<0.05$ ,  $I^2=64\%$ ) (S7). Conversely, the corrected meta-analysis  
280 suggested no effect ( $OR_{\text{Trim\&Fill}} = 1.07$ , CI 95% [0.89–1.30]). Correcting for publication bias  
281 led to a loss of the association and a 18% nonsignificant change in the association estimate  
282 ( $ROR_{\text{Trim\&Fill}} = 0.82$ , CI 95% 0.64–1.04) (Table 3).

283 The corrected meta-analysis using RoBMA also suggested no effect ( $OR_{\text{RoBMA}}=1.02$ , CI 95%  
284 1.00–1.33) in the sensitivity analysis. Correcting for publication bias resulted in a loss of the  
285 observed association, with a 23% significant change in the association estimate  
286 ( $ROR_{\text{RoBMA}}=0.77$ , CI 95% 0.55–0.86) (Table 3).

#### 287 *Secondary analysis*

##### 288 *Detection of the presence of publication bias by statin type*

289 We examined subgroups by statin type by incorporating 16 point estimates for simvastatin, 15  
290 for atorvastatin, and 12 for rosuvastatin. The visual inspection of funnel plots and Egger's tests  
291 suggested the presence of publication bias for simvastatin and atorvastatin (Figure 3 and Table  
292 3). However, the visual inspection for atorvastatin revealed an asymmetry caused by non-  
293 significant point estimates. For rosuvastatin, the funnel plot and Egger's test were not  
294 suggestive of publication bias.

295 The sensitivity analysis with RoBMA showed weak evidence of publication bias for  
296 simvastatin  $BF_{\text{Publication-bias}} = 2.73$  and atorvastatin  $BF_{\text{Publication-bias}} = 3.13$ . We did not perform  
297 this analysis for rosuvastatin because of the result of the Egger's test.

#### 298 *Evaluation of the impact of publication bias in secondary analysis by statin type*

299 Only simvastatin and atorvastatin uncorrected meta-analyses were statistically significant  
300 (Table 4), with substantial heterogeneity for simvastatin (Cochran's Q test  $p=0.02$ ,  $I^2=77\%$ ) and  
301 atorvastatin (Cochran's Q test  $p=0.02$ ,  $I^2=5\%$ ) (S7). Correction for publication bias with the  
302 T&F's method resulted in the loss of association for simvastatin ( $OR_{\text{Trim\&Fill}}=1.00$ , CI 95%  
303 0.58–1.72) and atorvastatin ( $OR_{\text{Trim\&Fill}}=1.13$ , CI 95% 0.89–1.43). Correcting for publication  
304 bias led to a loss of the association for simvastatin and atorvastatin with a 40% and 16%  
305 nonsignificant change in the association estimate, respectively (Table 3).

306 The corrected meta-analysis for simvastatin ( $OR_{\text{RoBMA}}=1.11$ , CI 95% 0.91–2.08) and  
307 atorvastatin ( $OR_{\text{RoBMA}}=1.02$  CI 95% 0.93–1.36) using RoBMA was also inconclusive.  
308 Correcting for publication bias led to a loss of the association, with a 34% and 24%  
309 nonsignificant change in the association estimate, respectively (Table 3).

#### 310 *Detection of the presence of publication bias by SNP type*

311 When subgrouping according to SNP type, we included 42 point estimates for rs4149056, 14  
312 point estimates for rs2306283, and 6 point estimates for rs4363657 with substantial  
313 heterogeneity for rs4149056 (Cochran's Q test  $p<0.001$ ,  $I^2=65\%$ ) and moderate heterogeneity  
314 for rs2306283 (Cochran's Q test  $p=0.5$ ,  $I^2=35\%$ ) and rs4363657 (Cochran's Q test  $p=0.1$ ,  $I^2=0\%$ )  
315 (S7). Visual inspection of the funnel plot for rs4149056 was suggestive of publication bias  
316 (Figure 4), consistent with Egger's test (Table 2). Conversely, it was not suggestive for SNP  
317 rs2306283 with nonsignificant Egger's test ( $p=0.8$ ) and undeterminable for rs4363657.

318 The sensitivity analysis with RoBMA showed moderate evidence of publication bias  
319 ( $BF_{\text{Publication bias}}=6$ ) for rs4149056. We did not perform this analysis for SNP rs2306283 and  
320 rs4363657.

#### 321 *Evaluation of the impact of publication bias by SNP type*

322 In the uncorrected meta-analysis, we observed a significant association only for rs4149056  
323 ( $OR_{\text{Uncorrected}}=1.63$ , CI 95% 1.34–1.99). Correction for publication bias with the T&F's method  
324 resulted in loss of the association ( $OR_{\text{Trim\&Fill}}=1.23$ , CI 95% 0.96–1.58) and a 25%  
325 nonsignificant change in the association estimate ( $ROR_{\text{Trim\&Fill}}=0.76$ , CI 95% 0.55–1.04)  
326 (Table 3).

327 The correction using RoBMA also resulted in loss of the significance of the association  
328 ( $OR_{\text{RoBMA}}=1.11$ , CI 95% 1.00–1.77) and a 32% significant change in the association estimate  
329 ( $ROR_{\text{RoBMA}}=0.68$ , CI 95% 0.55–0.85) (Table 3).

#### 330 *Other secondary analyses*

331 For secondary analyses focusing on rs4149056, visual inspection of the funnel plots suggested  
332 the presence of publication bias for simvastatin, atorvastatin, mixed statin, heterozygous, and  
333 homozygous comparisons (S8-9). Egger's tests were significant only for simvastatin and  
334 heterozygous comparisons, and RoBMA was in favor of publication bias. The corrected meta-  
335 analysis for simvastatin ( $OR_{\text{Trim\&Fill}}=1.04$ , CI 95% 0.55-1.96) and heterozygous comparison  
336 ( $OR_{\text{Trim\&Fill}}=1.04$ , CI 95% 0.75-1.44) was inconclusive, as was the sensitivity analysis using  
337 RoBMA (S10).

#### 338 *Exploratory analyses*

339 The results of the exploratory analysis do not suggest the presence of any notable publication  
340 bias, either in terms of type of statin used or study sponsor and ethnic group (S11–13).

341

## 342 DISCUSSION

### 343 *Summary of evidence and implication*

344 In our meta-epidemiologic study, we demonstrated the presence of publication bias in the  
345 pharmacogenetics of SAMS. This publication bias was sufficient to explain the suggested  
346 association. Our findings are corroborated by the sensitivity analyses using state of the art  
347 methods. To our knowledge, our meta-epidemiologic study is the first to specifically assess  
348 publication bias in pharmacogenetics of SAMS.

349 Previous meta-analyses generally used a small number of estimates (*i.e.*, <10) or did not assess  
350 publication bias [36–41]. This may explain why this publication bias was not brought to light  
351 earlier. Nevertheless, Jiang *et al.* reported potential publication bias for the heterozygote  
352 comparison and the dominant model, but did not use a method to correct this bias [18]. We also  
353 detected publication bias for the heterozygote comparison, and correction of this resulted in a  
354 loss of the association (Table 2, Table 3). However, we were not able to assess publication bias  
355 for the dominant model, due to the low number of estimates ( $k = 5$ ). Xiang *et al.* highlighted  
356 potential publication bias for the heterozygote comparison, the dominant and allelic model, and  
357 corrected this bias with the trim and fill method, which resulted in a loss of association for the  
358 heterozygote comparison [19]. As for Jiang *et al.*, we found publication bias for the  
359 homozygous comparison and the correction also resulted in the loss of the association.  
360 However, we did not perform the test for the allelic model due to the low number of associations  
361 ( $k = 8$ ), like the dominant model ( $k = 5$ ). Their studies may have lacked the power to detect  
362 global publication bias in pharmacogenetics of SAMS, but remain consistent with our results.

363 Consequently, our results cast doubt on the validity of adjusting statin dose or type according  
364 to SLCO1B1 genotype in patients in daily clinical practice. The association between SLCO1B1  
365 polymorphisms and SAMS needs to be specifically evaluated in a methodologically appropriate  
366 study before further investigating its clinical use, as it may be a false-positive. The



367 pharmacogenetic guidelines should take the publication bias into account when formulating  
368 guidance. Furthermore, all pharmacogenetic clinical studies should also be *a priori* registered  
369 and systematically published, independent of their results.

### 370 *Strengths of the study*

371 In our study, we assessed any publication bias using many point estimates (*i.e.* between 10 and  
372 62), with different levels of heterogeneity (*i.e.*  $I^2$  between 0 % and 79 %), with complementary  
373 methods such as funnel plots, Egger's test, T&F's method. To make our publication bias  
374 assessment more reliable, we extended our analyses to the RoBMA method. This recent  
375 approach has several advantages: first, the Bayesian framework allows us to provide evidence  
376 for or against publication bias without having to make all-or-nothing decisions of frequentist  
377 publication bias tests with BF [28]. Secondly, this method uses multiple selection models, which  
378 are considered the most reliable methods for detecting publication bias when there is significant  
379 heterogeneity [30]. RoBMA also provides a more insightful interpretation of results with the  
380 use of BF, which provides a continuous measure of evidence for the presence or absence of  
381 effect, heterogeneity and publication bias. This approach gave supportive evidence for  
382 publication bias, reinforcing our previous findings using conventional techniques. We corrected  
383 publication bias using T&F method and RoBMA, which resulted in loss of the association in  
384 the main analysis and in the subgroups studied. These results raise questions about the strength  
385 of the association originally reported and underscore the critical importance of assessing  
386 publication bias in meta-analyses. The observed loss of association may be explained by the  
387 fact that some negative or less pronounced estimates in favor of an increased risk of SAMS  
388 may have been underrepresented or less frequently published, leading to an overestimation of  
389 the association in the literature. Other factors, such as publication practices or P-hacking, may  
390 have exacerbated publication bias too [42]. The source of publication bias was also investigated.  
391 We examined the asymmetry of the funnel plots showing the main association by statin type or

392 sponsor of the original clinical trials. We observed that simvastatin contributed to the  
393 asymmetry of the funnel plot. Analysis by funding type showed that estimates from industry-  
394 funded trials had a non-significative trend (S12).

### 395 *Limitations*

396 Our study is subject to several limitations. Regarding the limitations of the evidence included  
397 in the review, all trials have an observational design for testing the association between a  
398 potential biomarker and the treatment effect. Therefore, the potential treatment effect  
399 modification is estimated with the corresponding high risk of bias, not protected by  
400 randomization. Considering the limits of the review process itself, first, none of the publication  
401 bias correction methods can be considered fully reliable, as the actual data generation process  
402 remains unknown. Factors, such as the degree of P-hacking, the degree of publication bias and  
403 heterogeneity may influence the results. Therefore, despite our efforts to correct publication  
404 bias, it is important to remain cautious when interpreting the results and to recognize the  
405 inherent limitations of any statistical correction for this type of bias. Secondly, use of many  
406 point estimates has resulted in significant heterogeneity, which may have influenced the  
407 detection of publication bias using classical symmetry methods – funnel plots, Egger’s test and  
408 T&F –, but we obtained consistent results with RoBMA, which strengthens the credibility of  
409 our conclusions. Thirdly, we did not use the T&F and RoBMA methods if Egger’s test was not  
410 significant. A negative regression test does not guarantee the absence of publication bias [43].  
411 We could have used a 10% significance level to compensate for its low power [24]. This would  
412 have made the analyses of several subgroups significant (Table 3, S10), but we preferred to  
413 minimize the risk of false positives. In addition, searching for interactions by ROR calculation  
414 is associated with a lack of power [44]. Nevertheless, the results of our study are all the stronger  
415 for having underestimated publication bias in most of our analyses. In addition, the effect of  
416 publication bias was more pronounced for simvastatin, which is known to be a more important

417 substrate of the OATP transporter (SLCO1B1). It would have been interesting to also evaluate  
418 the BCRP (ABCG2) transporter with other statins less affected by publication bias that are also  
419 substrates of this transporter. This could be an important addition to a future study. We chose to  
420 focus on SCLO1B1 because it is the focus of the recent CPIC recommendations.

## 421 Conclusion

422 In this meta-epidemiological study, we provide a cluster of consistent evidence of publication  
423 bias in the SLCO1B1- SAMS association. Our analysis revealed the presence of publication  
424 bias, which after correction, resulted in the loss of significance of the association. Given the  
425 limitations of publication bias adjustment methods, these results do not definitively rule out this  
426 association, but they call it into question. This publication bias should be considered in further  
427 research. Indeed, failing to consider the risk of publication bias in this example might lead to  
428 failure to treat patients who stand to benefit from statins.

429

430

## 431 Acknowledgment

432 We would like to thank Gaëlle Siméon for her help in reviewing this article.

## 433 Sources of Funding

434 AG was funded by RCTs through a ‘CIFRE’ PhD at the UMR 5558, Université Lyon 1,  
435 CNRS.

## 436 Disclosures

437 AG, IA, SG, JCL, JMW, CV, AL, FG, GG declare that they have no competing interest.

## 438 Author Contributions

439 Conceptualization: AG, GG, FG, AL, IA. Data curation: AG, IA, SG. Formal analysis: AG

440 Investigation: AG, GG, FG, AL, JCL. Methodology: AG, GG, FG, AL. Writing– original

441 draft: AG, GG. Writing– review & editing: AG, GG, FG, AL, IA, SG, JCL, JMW, CV

442

443 **Supplemental Materials**

444 S1: PRISMA checklist

445 S2: Search strategy (Pubmed, Embase, Cochrane central)

446 S3: Table Overlap primary studies in systematic reviews and risk of bias assessment in  
447 selected systematic review using the Newcastel-Ottawa scale (NOS)

448 S4: Formula of the ratio of odds ratio and its 95% confidence interval

449 S5: Assessment of the risk of bias (Score for Genetic Association Studies) in original clinical  
450 studies included by Turongkaravee et al. 2021

451 S6: Bayes factor for the primary and secondary analyses

452 S7: Proportion of heterogeneity in overall association and subgroups

453 S8–9: Supplementary funnel plot focused on rs4149056

454 S10: Table of supplementary results focused on rs4149056

455 S11: Funnel plot of the primary analysis based on statin type

456 S12: Funnel plot of the primary analysis based on study sponsor

457 S13: Funnel plot of the primary analysis based on study ethnic group

458

## 459 References

- 460 [1] Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The Effect of  
461 Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol  
462 Levels. *N Engl J Med* 1996;335:1001–9. <https://doi.org/10.1056/NEJM199610033351401>.
- 463 [2] Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol  
464 lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  
465 *Lancet Lond Engl* 2002;360:7–22. [https://doi.org/10.1016/S0140-6736\(02\)09327-3](https://doi.org/10.1016/S0140-6736(02)09327-3).
- 466 [3] Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to  
467 Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. *N Engl J Med*  
468 2008;359:2195–207. <https://doi.org/10.1056/NEJMoa0807646>.
- 469 [4] Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, Dixon DL, et al. Assessment and  
470 management of statin-associated muscle symptoms (SAMS): A clinical perspective from the  
471 National Lipid Association. *J Clin Lipidol* 2023;17:19–39.  
472 <https://doi.org/10.1016/j.jacl.2022.09.001>.
- 473 [5] Romaine SPR, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene  
474 polymorphisms on response to statin therapy. *Pharmacogenomics J* 2010;10:1–11.  
475 <https://doi.org/10.1038/tpj.2009.54>.
- 476 [6] Link L. SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. *N Engl J Med*  
477 2008;359:789–99. <https://doi.org/10.1056/NEJMoa0801936>.
- 478 [7] Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, et al. Differential effect of  
479 the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.  
480 *Pharmacogenomics J* 2012;12:233–7. <https://doi.org/10.1038/tpj.2010.92>.
- 481 [8] Voora D, Shah S, Spasojevic I, Ali S, Reed C, Salisbury B, et al. The SLCO1B1\*5 genetic variant  
482 is associated with statin-induced side effects. *J Am Coll Cardiol* 2009;54:1609-1616.  
483 <https://doi.org/10.1016/j.jacc.2009.04.053>.
- 484 [9] Carr DF, O’Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, et al. SLCO1B1 genetic  
485 variant associated with statin-induced myopathy: a proof-of-concept study using the clinical  
486 practice research datalink. *Clin Pharmacol Ther* 2013;94:695–701.  
487 <https://doi.org/10.1038/clpt.2013.161>.
- 488 [10] Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. Lack of association  
489 between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.  
490 *Pharmacoepidemiol Drug Saf* 2012;21:185–6. <https://doi.org/10.1002/pds.3324>.
- 491 [11] Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data  
492 from an observational case-control study. *Atherosclerosis* 2010;211:28–9.  
493 <https://doi.org/10.1016/j.atherosclerosis.2010.02.026>.
- 494 [12] Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The  
495 Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and  
496 CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. *Clin Pharmacol Ther*  
497 2022;111:1007–21. <https://doi.org/10.1002/cpt.2557>.
- 498 [13] Obeng AO, Scott SA, Kaszemacher T, Ellis SB, Mejia A, Gomez A, et al. Prescriber Adoption of  
499 SLCO1B1 Genotype-Guided Simvastatin Clinical Decision Support in a Clinical  
500 Pharmacogenetics Program. *Clin Pharmacol Ther* 2023;113:321–7.  
501 <https://doi.org/10.1002/cpt.2773>.
- 502 [14] Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective Publication of  
503 Antidepressant Trials and Its Influence on Apparent Efficacy. *N Engl J Med* 2008;358:252–60.  
504 <https://doi.org/10.1056/NEJMsa065779>.
- 505 [15] Wang C-H, Li C-H, Hsieh R, Fan C-Y, Hsu T-C, Chang W-C, et al. Proton pump inhibitors  
506 therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized  
507 controlled trials and observational studies. *Expert Opin Drug Saf* 2019;18:163–72.  
508 <https://doi.org/10.1080/14740338.2019.1577820>.
- 509 [16] Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JPA. Local literature bias in genetic  
510 epidemiology: an empirical evaluation of the Chinese literature. *PLoS Med* 2005;2:e334.  
511 <https://doi.org/10.1371/journal.pmed.0020334>.

- 512 [17] Bally S, Cottin J, Gagnieu MC, Lega JC, Verstuyft C, Rheims S, et al. Publication bias in  
513 pharmacogenetics of adverse reaction to antiseizure drugs: An umbrella review and a meta-  
514 epidemiological study. *PloS One* 2022;17:e0278839.  
515 <https://doi.org/10.1371/journal.pone.0278839>.
- 516 [18] Jiang J, Tang Q, Feng J, Dai R, Wang Y, Yang Y, et al. Association between SLCO1B1 -521T>C  
517 and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis.  
518 *SpringerPlus* 2016;5:1368. <https://doi.org/10.1186/s40064-016-2912-z>.
- 519 [19] Xiang Q, Chen S-Q, Ma L-Y, Hu K, Zhang Z, Mu G-Y, et al. Association between SLCO1B1  
520 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. *Pharmacogenomics J*  
521 2018;18:721–9. <https://doi.org/10.1038/s41397-018-0054-0>.
- 522 [20] Duval S, Tweedie R. Trim and Fill: A Simple Funnel-Plot–Based Method of Testing and Adjusting  
523 for Publication Bias in Meta-Analysis. *Biometrics* 2000;56:455–63.  
524 <https://doi.org/10.1111/j.0006-341X.2000.00455.x>.
- 525 [21] Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane*  
526 *Handbook for Systematic Reviews of Interventions* version 6.3 (updated February 2022).  
527 Cochrane, 2022. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook). n.d.
- 528 [22] Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting  
529 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*  
530 2015;4:1. <https://doi.org/10.1186/2046-4053-4-1>.
- 531 [23] Krnic Martinic M, Pieper D, Glatt A, Puljak L. Definition of a systematic review used in  
532 overviews of systematic reviews, meta-epidemiological studies and textbooks. *BMC Med Res*  
533 *Methodol* 2019;19:1–12. <https://doi.org/10.1186/s12874-019-0855-0>.
- 534 [24] Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple,  
535 graphical test. *BMJ* 1997;315:629–34. <https://doi.org/10.1136/bmj.315.7109.629>.
- 536 [25] Gombault C, Grenet G, Segurel L, Duret L, Gueyffier F, Cathébras P, et al. Population  
537 designations in biomedical research: Limitations and perspectives. *HLA* 2023;101:3–15.  
538 <https://doi.org/10.1111/tan.14852>.
- 539 [26] Warrens MJ. Inequalities between multi-rater kappas. *Adv Data Anal Classif* 2010;4:271–86.  
540 <https://doi.org/10.1007/s11634-010-0073-4>.
- 541 [27] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.  
542 *Biometrics* 1994;50:1088–101.
- 543 [28] Bartoš F, Maier M, Wagenmakers E, Doucouliagos H, Stanley TD. Robust Bayesian meta-  
544 analysis: Model-averaging across complementary publication bias adjustment methods. *Res Synth*  
545 *Methods* 2023;14:99–116. <https://doi.org/10.1002/jrsm.1594>.
- 546 [29] Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.  
547 *BMJ* 2003;327:557–60. <https://doi.org/10.1136/bmj.327.7414.557>.
- 548 [30] Maier M, VanderWeele TJ, Mathur MB. Using selection models to assess sensitivity to publication  
549 bias: A tutorial and call for more routine use. *Campbell Syst Rev* 2022;18:e1256.  
550 <https://doi.org/10.1002/cl2.1256>.
- 551 [31] Nobre A de P, de Melo GM, Shanks DR. Publication bias casts doubt on implicit processing in  
552 inattention blindness. *Neurosci Biobehav Rev* 2022;140:104775.  
553 <https://doi.org/10.1016/j.neubiorev.2022.104775>.
- 554 [32] Holgado D, Mesquida C, Román-Caballero R. Assessing the Evidential Value of Mental Fatigue  
555 and Exercise Research. *Sports Med Auckl NZ* 2023. <https://doi.org/10.1007/s40279-023-01926-w>.
- 556 [33] Borawski J, Papadatou-Pastou M, Packheiser J, Ocklenburg S. Handedness in post-traumatic  
557 stress disorder: A meta-analysis. *Neurosci Biobehav Rev* 2023;145:105009.  
558 <https://doi.org/10.1016/j.neubiorev.2022.105009>.
- 559 [34] R Core Team (2022). *R: A language and environment for statistical computing*. R Foundation for  
560 Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>. n.d.
- 561 [35] Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial.  
562 *Evid Based Ment Health* 2019;22:153–60. <https://doi.org/10.1136/ebmental-2019-300117>.
- 563 [36] Hou Q, Li S, Li L, Li Y, Sun X, Tian H. Association Between SLCO1B1 Gene T521C  
564 Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.  
565 *Medicine (Baltimore)* 2015;94:e1268. <https://doi.org/10.1097/MD.0000000000001268>.



- 566 [37]de Keyser CE, Peters BJM, Becker ML, Visser LE, Uitterlinden AG, Klungel OH, et al. The  
567 SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin  
568 therapy in the Rotterdam Study. *Pharmacogenet Genomics* 2014;24:43.  
569 <https://doi.org/10.1097/FPC.000000000000018>.
- 570 [38]Nguyen KA, Li L, Lu D, Yazdanparast A, Wang L, Kreutz RP, et al. A comprehensive review and  
571 meta-analysis of risk factors for statin-induced myopathy. *Eur J Clin Pharmacol* 2018;74:1099–  
572 109. <https://doi.org/10.1007/s00228-018-2482-9>.
- 573 [39]Turongkaravee S, Jittikoon J, Lukkunaprasit T, Sangroongruangsri S, Chaikledkaew U,  
574 Thakkinstian A. A systematic review and meta-analysis of genotype-based and individualized data  
575 analysis of SLCO1B1 gene and statin-induced myopathy. *Pharmacogenomics J* 2021;21:296–307.  
576 <https://doi.org/10.1038/s41397-021-00208-w>.
- 577 [40]Du Y, Wang S, Chen Z, Sun S, Zhao Z, Li X. Association of SLCO1B1 Polymorphisms and  
578 Atorvastatin Safety and Efficacy: A Meta-analysis. *Curr Pharm Des* 2018;24:4044–50.  
579 <https://doi.org/10.2174/1381612825666181219163534>.
- 580 [41]Xiang Q, Zhang X-D, Mu G-Y, Wang Z, Liu Z-Y, Xie Q-F, et al. Correlation between single-  
581 nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis.  
582 *Eur J Clin Pharmacol* 2021;77:569–81. <https://doi.org/10.1007/s00228-020-03029-1>.
- 583 [42]Ioannidis JPA. Why Most Published Research Findings Are False. *PLoS Med* 2005;2:e124.  
584 <https://doi.org/10.1371/journal.pmed.0020124>.
- 585 [43]Ioannidis JPA, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in  
586 meta-analyses: a large survey. *CMAJ Can Med Assoc J* 2007;176:1091–6.  
587 <https://doi.org/10.1503/cmaj.060410>.
- 588 [44]Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in  
589 treatment effect estimates in controlled trials with different interventions and outcomes: meta-  
590 epidemiological study. *BMJ* 2008;336:601. <https://doi.org/10.1136/bmj.39465.451748.AD>.
- 591



593 Table 1: Characteristics of the clinical studies collected through the included systematic reviews

Author	Publication date	Design of study	Type of follow up	Type of statin	SNPs
Bai et al.	2019	Cohort	Prospective	Rosuvastatin	rs2306283,rs4149056, rs4363657
Bakar et al.	2017	Case-control	Retrospective	Mixed	rs4149056
Brunham et al.	2011	Case-control	Retrospective	Atorvastatin, Simvastatin Mixed	rs4149056
Carr et al.	2013	Case-control	Retrospective	Atorvastatin, Simvastatin, Mixed	rs4149056
Danik et al.	2013	Cohort from RCT	Retrospective	Rosuvastatin	rs4149056, rs4363657
de Keyser et al.	2014	Cohort	Retrospective	Atorvastatin, Simvastatin	rs4149056
Donnelly et al.	2011	Cohort	Retrospective	Mixed	rs2306283, rs4149056
Ferrari et al.	2014	Case-control	Prospective	Mixed	rs2306283, rs4149056
Hubacek et al.	2015	Case-control	Prospective	Simvastatin, Mixed	rs4363657
Khine et al.	2017	Case-control	Retrospective	Simvastatin, Mixed	rs4149056
Linde et al.	2010	Cohort	Retrospective	Mixed	rs4149056

<b>Author</b>	<b>Publication date</b>	<b>Design of study</b>	<b>Type of follow up</b>	<b>Type of statin</b>	<b>SNPs</b>
<b>Link et al.</b>	2008	Case-control from RCT	Retrospective	Simvastatin	rs4149056, rs4363657
<b>Liu et al.</b>	2017	Case-control	Retrospective	Atorvastatin, Rosuvastatin, Simvastatin, Mixed	rs2306283, rs4149056
<b>Marciante et al.</b>	2011	Case-control	Prospective	Cerivastatin	rs4149056
<b>Mirosevic Skvrce et al.</b>	2015	Case-control	NC	Atorvastatin	rs2306283, rs4149056
<b>Sai et al.</b>	2016	Cohort	Retrospective	Mixed	rs4149056
<b>Santos et al.</b>	2012	Cohort	Prospective	Atorvastatin	rs2306283, rs4149056
<b>Voora et al.</b>	2009	Cohort	Retrospective	Atorvastatin, Pravastatin, Simvastatin, Mixed	rs4149056
<b>Willrich et al.</b>	2018	Case-control	NC	Mixed	rs2306283, rs4149056

594

595 Mixed: statins used indifferently, SNPs: single nucleotide polymorphism, NC: not communicated

596 **Table n°2 : Detection of publication bias in the primary and secondary analysis**

Association	k	Evaluation of publication bias		
		Funnel plot	Egger's test	RoBMA
<b>Primary analysis (overall)</b>	62	suggestive of a publication bias	0.001*	In favor <sup>+++</sup>
<b>By polymorphism type</b>				
<b>rs4149056</b>	42	suggestive of a publication bias	0.001*	In favor <sup>++</sup>
<b>rs2306283</b>	14	not suggestive of a publication bias	0.8	NE
<b>rs4363657</b>	6	not assessable	NA	NE
<b>By statin type</b>				
<b>Simvastatin</b>	16	suggestive of a publication bias	0.03*	In favor <sup>++</sup>
<b>Atorvastatin</b>	15	suggestive of a publication bias	0.02*	In favor <sup>+</sup>
<b>Rosuvastatin</b>	12	not suggestive of a publication bias	0.1	NE

Association	k	Evaluation of publication bias		
		Funnel plot	Egger's test	RoBMA
<b>Statin mixed</b>	17	not suggestive of a publication bias	0.2	NE
<b>Cerivastatin</b>	1	not assessable	NA	NA
<b>Pravastatin</b>	1	not assessable	NA	NA
<b>By genetic model</b>				
<b>Homozygous comparison</b>	24	suggestive of a publication bias	0.01*	In favor <sup>+</sup>
<b>Heterozygous comparison</b>	25	not suggestive of a publication bias	0.02*	In favor <sup>+</sup>
<b>Dominant model</b>	5	not assessable	NA	NA
<b>Allelic model</b>	8	not assessable	NA	NA

597

598 k: number of point estimates include in assessment, \* indicates significant p-value, NA: not applicable, NE: not executed, <sup>+++</sup> indicates Bayes  
599 factor <10, <sup>++</sup> indicates Bayes factor 3-10, <sup>+</sup> indicates Bayes factor <3

600

601 **Table 3: Estimate and correction of publication bias in the primary and secondary analysis**

Association	k	OR <sub>Uncorrected</sub> CI95%	OR <sub>Corrected</sub> CI95%		Effect of publication bias	
			OR <sub>Trim&amp;Fill</sub>	OR <sub>RoBMA</sub>	ROR <sub>T&amp;F</sub> 95%CI	ROR <sub>RoBMA</sub> 95%CI
Primary analysis (overall)	62	1.31 [1.13 - 1.53]	1.07 [0.89 - 1.30]	1.02 [1.00 - 1.33]	0.82 [0.64 - 1.04]	0.77 [0.66 - 0.90]
<b>By polymorphism type</b>						
rs4149056	42	1.63 [1.34 - 1.99]	1.23 [0.96 - 1.58]	1.11 [1.00 - 1.77]	0.76 [0.55 - 1.04]	0.68 [0.55 - 0.86]
rs2306283	14	0.94 [0.76 - 1.15]	NE			
rs4363657	6	0.90 [0.79 - 1.03]	NE			
<b>By statin type</b>						
Simvastatin	16	1.68 [1.08 - 2.61]	1.00 [0.58 - 1.72]	1.11 [0.91 - 2.08]	0.60 [0.30 - 1.20]	0.66 [0.41 - 1.07]
Atorvastatin	15	1.34 [1.04 - 1.73]	1.13 [0.89 - 1.43]	1.02 [0.93 - 1.36]	0.84 [0.59 - 1.19]	0.76 [0.58 - 0.86]
Rosuvastatin	12	1.22 [0.93 - 1.60]	NE			
Statin mixed	17	1.07 [0.83 - 1.38]	NE			
Cerivastatin	1	NA				
Pravastatin	1	NA				
<b>By genetic model</b>						
Homozygous comparison	24	1.55 [1.08 - 2.21]	1.04 [0.65 - 1.66]	1.10 [0.99 - 1.85]	0.84 [0.62 - 1.15]	0.84 [0.68 - 1.03]
Heterozygous comparison	25	1.20 [0.99 - 1.47]	1.01 [0.79 - 1.29]	1.01 [0.95 - 1.22]	0.67 [0.37 - 1.21]	0.71 [0.49 - 1.03]


Association	k	OR <sub>Uncorrected</sub> CI95%	OR <sub>Corrected</sub> CI95%		Effect of publication bias	
			OR <sub>Trim&amp;Fill</sub>	OR <sub>RoBMA</sub>	ROR <sub>T&amp;F</sub> 95%CI	ROR <sub>RoBMA</sub> 95%CI
Dominant model	5	1.59 [1.03 - 2.47]	NA			
Allelic model	8	1.28 [0.85 - 1.93]	NA			

602


603 k: number of point estimates, NA: not applicable, NE: not executed, because of non-significant Egger's test, ROR<sub>Trim&Fill</sub>: ratio of OR<sub>Trim&Fill</sub> and

604 OR<sub>Uncorrected</sub>; ROR<sub>RoBMA</sub>: ratio of OR<sub>Robust Bayesian Meta-Analysis</sub> and OR<sub>Uncorrected</sub>

605 **Figures**




643 Figure 1: Flow chart diagram of bibliographic search



644


645 **Figure 2: Funnel plot of the primary analysis (k = 62) [SLCO1B1 polymorphisms – Statins – SAMS]** - Funnel plot of the association between  
 646 [SLCO1B1 – Statin – SAMS] k: number of point estimates. In the funnel plot, each point is an estimation of the associations. The white, dark and light grey  
 647 zones stand for a p-value of the odds ratio i) non-significant, ii) between 0.05 and 0.01, and iii) <0.01, respectively. The dashed triangle stands for the estimation  
 648 of the meta-analysis of the association, without adjusting for a potential publication bias.





649

650 **Figure 3: Funnel plots of subgroups by type of statin** - Funnel plot of the association between, A [SLCO1B1 – Simvastatin – SAMS k = 16], B [SLCO1B1  
 651 – Atorvastatin – SAMS k = 15], C [SLCO1B1 – Rosuvastatin – SAMS k = 12]. k: number of point estimates. In the funnel plots, each point is an estimation of  
 652 the associations. The white, dark and light grey zones stand for a p-value of the odds ratio i) non-significant, ii) between 0.05 and 0.01, and iii) <0.01, respectively.  
 653 The dashed triangle stands for the estimation of the meta-analysis of the association, without adjusting for a potential publication bias.



654

655 **Figure 4: Funnel plots of subgroups by type of SNP** - Funnel plot of the association between A [rs4149056– Statins – SAMS k = 42], B [rs2306283–  
 656 Statins – SAMS k = 14], C [rs4363657 – Statins – SAMS k = 6]. k: number of point estimates. In the funnel plots, each point is an estimation of the associations.  
 657 The white, dark and light grey zones stand for a p value of the odds ratio i) non-significant, ii) between 0.05 and 0.01, and iii)  $< 0.01$ , respectively.  
 658 The dashed triangle stands for the estimation of the meta-analysis of the association, without adjusting for a potential publication bias.

## 659 Supplemental Material

660 *Supplementary material 1 (S1): PRISMA check list*

Section and Topic	Item #	Checklist item	Location where item is reported
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	<a href="#">Title</a>
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	<a href="#">Abstract (348 words)</a>
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	<a href="#">INTRODUCTION</a>
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	<a href="#">INTRODUCTION</a>
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	<a href="#">Search strategy and inclusion criteria</a>
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	<a href="#">Search strategy and inclusion criteria</a>
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	<a href="#">Supplementary 1 (S1) : Search strategy</a>
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	<a href="#">Search strategy and inclusion criteria</a>
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	<a href="#">Data extraction and quality assessment of included studies</a>
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	<a href="#">Data extraction and quality assessment of included studies</a>
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	<a href="#">Data extraction and quality</a>

Section and Topic	Item #	Checklist item	Location where item is reported
			<a href="#">assessment of included studies</a>
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	<a href="#">Data extraction and quality assessment of included studies</a>
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	<a href="#">Dataset</a>
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	<a href="#">Outcome</a>
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	<a href="#">Statistical analysis</a>
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	<a href="#">Statistical analysis</a>
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	<a href="#">Statistical analysis</a>
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	<a href="#">Statistical analysis</a>
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	<a href="#">Statistical analysis</a>
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	<a href="#">Statistical analysis</a>
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	<a href="#">Statistical analysis</a>
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	<a href="#">Figures: flow chart</a>
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	<a href="#">Figures: flow chart</a>
Study characteristics	17	Cite each included study and present its characteristics.	<a href="#">Tables: characteristics of include studies</a>
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	<a href="#">Supplementary 5.(1-2): Risk of bias assessment in selected</a>

Section and Topic	Item #	Checklist item	Location where item is reported
			<a href="#">systematic review</a>
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	X
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	<a href="#">Supplementary 5.(1-2): Risk of bias assessment in selected systematic review</a>
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	<a href="#">Tables: results</a>
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	<a href="#">Assessment of publication bias in the main association</a>
			<a href="#">Assessment of publication bias in subgroup</a>
20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	<a href="#">Assessment of publication bias in the main association</a>  <a href="#">Assessment of publication bias in subgroup</a>	
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	<a href="#">Assessment of publication bias in the main association</a>  <a href="#">Assessment of publication bias in subgroup</a>
Certainty of	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	<a href="#">Assessment of</a>

Section and Topic	Item #	Checklist item	Location where item is reported
evidence			<a href="#">publication bias in the main association</a>  <a href="#">Assessment of publication bias in subgroup</a>
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	<a href="#">Summary of evidence Strengths of the study</a>
	23b	Discuss any limitations of the evidence included in the review.	<a href="#">Limitations</a>
	23c	Discuss any limitations of the review processes used.	<a href="#">Limitations</a>
	23d	Discuss implications of the results for practice, policy, and future research.	<a href="#">Summary of evidence</a>
<b>OTHER INFORMATION</b>			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	<a href="#">Protocol and registration</a>
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	<a href="#">Protocol and registration</a>
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	<a href="#">Protocol and registration</a>
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	<a href="#">Sources of Funding</a>
Competing interests	26	Declare any competing interests of review authors.	<a href="#">Disclosures</a>
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	<a href="#">Supplemental Material</a>

661  
662

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

663 *Supplementary material (S2): Search strategy*

664 *Pharmacogenomics keywords* : ("polymorphism, genetic"[MeSH Terms] OR ("polymorphism"[All  
665 Fields] AND "genetic"[All Fields]) OR "genetic polymorphism"[All Fields] OR ("polymorphism"[All  
666 Fields] AND "genetic"[All Fields]) OR "polymorphism genetic"[All Fields] OR ("organic anion  
667 transporters"[MeSH Terms] OR ("organic"[All Fields] AND "anion"[All Fields] AND  
668 "transporters"[All Fields]) OR "organic anion transporters"[All Fields] OR ("solute"[All Fields] AND  
669 "carrier"[All Fields] AND "organic"[All Fields] AND "anion"[All Fields]) OR "solute carrier organic  
670 anion"[All Fields] AND ("biological transport"[MeSH Terms] OR ("biological"[All Fields] AND  
671 "transport"[All Fields]) OR "biological transport"[All Fields] OR "transport"[All Fields] OR  
672 "membrane transport proteins"[MeSH Terms] OR ("membrane"[All Fields] AND "transport"[All  
673 Fields] AND "proteins"[All Fields]) OR "membrane transport proteins"[All Fields] OR  
674 "transporter"[All Fields] OR "transporters"[All Fields] OR "transportable"[All Fields] OR  
675 "transportation"[MeSH Terms] OR "transportation"[All Fields] OR "transportations"[All Fields] OR  
676 "transported"[All Fields] OR "transporter s"[All Fields] OR "transporting"[All Fields] OR  
677 "transports"[All Fields] AND "1B1"[All Fields]) OR "SLCO1B1"[All Fields] OR ("organic anion  
678 transporters"[MeSH Terms] OR ("organic"[All Fields] AND "anion"[All Fields] AND  
679 "transporters"[All Fields]) OR "organic anion transporters"[All Fields] OR ("organic"[All Fields]  
680 AND "anion"[All Fields] AND "transporter"[All Fields]) OR "organic anion transporter"[All Fields])  
681 AND ("peptides"[MeSH Terms] OR "peptides"[All Fields] OR "polypeptide"[All Fields] OR  
682 "polypeptides"[All Fields] OR "polypeptid"[All Fields] OR "polypeptide s"[All Fields] OR  
683 "polypeptidic"[All Fields] AND "1B1"[All Fields]) OR "OATP1B1"[All Fields])

684 AND

685 *Statin keywords* : statin OR rosuvastatin OR fluvastatin OR pravastatin ("hydroxymethylglutaryl coa  
686 reductase inhibitors"[Pharmacological Action] OR "hydroxymethylglutaryl coa reductase  
687 inhibitors"[MeSH Terms] OR ("hydroxymethylglutaryl coa"[All Fields] AND "reductase"[All Fields]  
688 AND "inhibitors"[All Fields]) OR "hydroxymethylglutaryl coa reductase inhibitors"[All Fields] OR  
689 "statin"[All Fields] OR "statins"[All Fields] OR "statin s"[All Fields] OR "statine"[Supplementary  
690 Concept] OR "statine"[All Fields] OR "statines"[All Fields] OR ("rosuvastatin calcium"[MeSH  
691 Terms] OR ("rosuvastatin"[All Fields] AND "calcium"[All Fields]) OR "rosuvastatin calcium"[All  
692 Fields] OR "rosuvastatin"[All Fields]) OR ("fluvastatin"[MeSH Terms] OR "fluvastatin"[All Fields])  
693 OR ("pravastatin"[MeSH Terms] OR "pravastatin"[All Fields] OR "pravastatin s"[All Fields]) OR  
694 ("simvastatin"[MeSH Terms] OR "simvastatin"[All Fields] OR "simvastatin s"[All Fields] OR  
695 "simvastatins"[All Fields]) OR ("cerivastatin"[Supplementary Concept] OR "cerivastatin"[All Fields]  
696 OR "cerivastatin s"[All Fields]) OR ("lovastatin"[MeSH Terms] OR "lovastatin"[All Fields] OR  
697 "lovastatine"[All Fields] OR "lovastatin s"[All Fields]) OR ("atorvastatin"[MeSH Terms] OR  
698 "atorvastatin"[All Fields] OR "atorvastatine"[All Fields] OR "atorvastatin s"[All Fields]) OR  
699 ("pitavastatin"[Supplementary Concept] OR "pitavastatin"[All Fields]))

700 AND

701 *Adverse event keywords* : ("muscular diseases"[MeSH Terms] OR ("muscular"[All Fields] AND  
702 "diseases"[All Fields]) OR "muscular diseases"[All Fields] OR "myopathies"[All Fields] OR  
703 "myopathy"[All Fields] OR ("myalgia"[MeSH Terms] OR "myalgia"[All Fields] OR "myalgias"[All  
704 Fields]) OR ("myositis"[MeSH Terms] OR "myositis"[All Fields] OR "myositides"[All Fields]) OR  
705 ("rhabdomyolysis"[MeSH Terms] OR "rhabdomyolysis"[All Fields] OR "rhabdomyolyses"[All  
706 Fields]) OR ("creatine kinase"[MeSH Terms] OR ("creatine"[All Fields] AND "kinase"[All Fields])  
707 OR "creatine kinase"[All Fields]) OR "CK"[All Fields])

708 **Search strategy PubMed details**

709 *Pharmacogenomics keywords* : ('polymorphism genetic'/exp OR 'polymorphism genetic' OR  
710 (('polymorphism'/exp OR polymorphism) AND ('genetic'/exp OR genetic)) OR 'solute carrier organic  
711 anion transporter 1b1'/exp OR 'solute carrier organic anion transporter 1b1' OR (('solute'/exp OR  
712 solute) AND ('carrier'/exp OR carrier) AND organic AND ('anion'/exp OR anion) AND  
713 ('transporter'/exp OR transporter) AND 1b1) OR slco1b1 OR 'organic anion transporter polypeptide  
714 1b1' OR (organic AND ('anion'/exp OR anion) AND ('transporter'/exp OR transporter) AND  
715 ('polypeptide'/exp OR polypeptide) AND 1b1) OR oatp1b1)

716 AND

717 *Statin keywords*: ('statin'/exp OR statin OR 'rosuvastatin'/exp OR rosuvastatin OR 'fluvastatin'/exp OR  
718 fluvastatin OR 'pravastatin'/exp OR pravastatin OR 'simvastatin'/exp OR simvastatin OR  
719 'cerivastatin'/exp OR cerivastatin OR 'lovastatin'/exp OR lovastatin OR 'atorvastatin'/exp OR  
720 atorvastatin OR 'pitavastatin'/exp OR pitavastatin)

721 AND

722 *Adverse event keywords*: ('myopathy'/exp OR myopathy OR 'myalgia'/exp OR myalgia OR  
723 'myositis'/exp OR myositis OR 'rhabdomyolysis'/exp OR rhabdomyolysis OR 'creatine kinase'/exp OR  
724 'creatine kinase' OR (('creatine'/exp OR creatine) AND ('kinase'/exp OR kinase)) OR ck)

## 725 Search strategy Embase details

726

727 ID Search Hits

728 #1 polymorphism genetic

729 #2 solute carrier organic anion transporter 1B1

730 #3 SLCO1B1

731 #4 organic anion transporter polypeptide 1B1 OR OATP1B1

732 #5 #1 OR #2 OR #3 OR #4

733 #6 statin

734 #7 rosuvastatin

735 #8 pravastatin

736 #9 simvastatin

737 #10 cerivastatin

738 #11 lovastatin

739 #12 atorvastatin

740 #13 pitavastatin

741 #14 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13

742 #15 myopathy

743 #16 myalgia

744 #17 myositis



745 #18 rhabdomyolysis  
746 #19 creatine kinase  
747 #20 CK  
748 #21 #15 OR #16 OR #17 OR #18 OR #19 OR #20  
749 #22 #5 AND #14 #21  
750 **Search strategy Cochrane Central details**

751 *Supplementary material 3 (S3): Overlap primary studies in systematic reviews and risk*  
 752 *of bias assessment in selected systematic review using the Newcastle-Ottawa scale*  
 753 *(NOS)*

Clinical study	Systematic review					
	Hou et al. 2013	Jiang et al. 2016	Du et al. 2018	Xiang et al. 2018	Turongkaravee et al. 2021	Xiang et al. 2021
Link et al. 2008	9	8		9	X	
Voora et al. 2009	7	7	8	7	X	
Linde et al. 2010	6	5		6	X	6
Marciante 2011	9	5		8	X	8
Donnelly et al. 2011	7	7		7	X	8
Brunham et al. 2012	7	9	8	7	X	9
Santos et al. 2012	7	8	7	7		9
Carr et al. 2013	6	7	8	6	X	9
Danik et al. 2013		7		6		9
de Keyser et al. 2014		8				
Ferrari et al. 2014	8		7	8	X	9
Mirosevic Skvrce et al. 2015					X	
Hubacek et al. 2015				7		8
Sai et al. 2016				6	X	
Bakar et al. 2017				8	X	7
Khine et al. 2017					X	8
Liu et al. 2017				7		9
Willrich et al. 2018					X	
Bai et al. 2019					X	9

754  
 755 *Supplementary material 4 (S4): Formula of the ratio of odds ratio and its 95%*  
 756 *confidence interval*

757 
$$ROR = \exp\left(\log\left(\frac{OR \text{ corrected for publication bias}}{OR \text{ uncorrected for publication bias}}\right)\right)$$

758 
$$CI \ 95\% = \exp\left(\log(OR) \pm 1.96 * \left(\frac{\log(OR) - \log(IC_{low})}{1.96}\right)^2 + \left(\frac{\log(OR) - \log(IC_{up})}{1.96}\right)^2\right)^{0.5}$$

759

760 *Supplementary 5 (S5): Assessment of the risk of bias (Score for Genetic Association*  
 761 *Studies) in original clinical studies included by Turongkaravee et al. 2021*

No	Author	Year	Information bias			Confounding bias		Selective outcome report	HWE
			Ascertainment of case	Ascertainment of control	Ascertainment of genotyping examination	Population stratification	Other confounding bias		
1	Bai X, et al.	2018	●	●	●	●	●	●	●
2	Willrich, et al.	2018	●	●	●	●	●	●	●
3	Bakar, et al.	2017	●	●	●	●	●	●	●
4	Liu JE, et al.	2017	●	●	●	●	●	●	●
5	Khine H, et al.	2016	●	●	●	●	●	●	●
6	Sai K, et al.	2016	●	●	●	●	●	●	●
7	Mirošević S, et al.	2015	●	●	●	●	●	●	●
8	Ferrari M, et al.	2014	●	●	●	●	●	●	●
9	Carr DF, et al.	2013	●	●	●	●	●	●	●
10	Brunham LR, et al.	2012	●	●	●	●	●	●	●
11	Donnelly LA, et al.	2011	●	●	●	●	●	●	●
12	Marcante KD, et al.	2011	●	●	●	●	●	●	●
13	Linde R, et al.	2010	●	●	●	●	●	●	●
14	Voora D, et al.	2009	●	●	●	●	●	●	●
15	Link E, et al.	2008	●	●	●	●	●	●	●

● possible/high risk of bias   
 ● unclear or insufficient information to assess risk of bias   
 ● low/no risk of bias

762

763 *Supplementary material (S6): Bayes factor for the overall association and subgroups*

Association	k	BF effect	BF heterogeneity	BF publication bias	
<b>Overall</b>	62	0.13	510184	17.57	764
<i>By polymorphism type</i>					
<b>rs4149056</b>	42	0.46	10514	6.17	765
<i>rs4149056 by statin type</i>					
Simvastatin	13	0.81	1712	2.34	
Atorvastatin	11		NE		
Rosuvastatin	5		NA		
Mixed statin	11		NE		
Cerivastatin	1				
Pravastatin	1		NA		770
<i>rs4149056 by genetic model</i>					
Heterozygous comparison	17	0.20	27	3.96	771
Homozygous comparison	16		NE		772
Allelic model	5		NA		
Dominant model	4				
<b>rs2306283</b>	14		NE		
<b>rs4363657</b>	6		NA		
<i>By statin type</i>					
Simvastatin	16	0.42	823	2.73	
Atorvastatin	15	0.18	0.52	3.13	
Rosuvastatin	12		NE		
Mixed statin	17		NE		
Cerivastatin	1				
Pravastatin	1		NA		778
<i>By genetic model</i>					
Homozygous comparison	24	0.40	49	2.12	779
Heterozygous comparison	25	0.20	27	3.96	780
Dominant model	5		NA		
Allelic model	8		NE		781

782 k: number of point estimates, BF : Bayes factor, NA: not applicable, NE: not executed, because of non-significant Egger's test


783 *Supplementary material 7 (S7): Proportion of heterogeneity in primary analysis and*  
 784 *secondary analysis*

<b>Association</b>	<b>k</b>	<b>I<sup>2</sup></b>
<b>Primary analysis</b>	62	64
<i>By statin type</i>		
<b>Simvastatin</b>	16	77
<b>Atorvastatin</b>	15	4
<b>Rosuvastatin</b>	12	53
<b>Mixed statin</b>	17	62
<b>Cerivastatin</b>	1	NE
<b>Pravastatin</b>	1	NE
<i>By genetic model</i>		
<b>Homozygous model</b>	24	63
<b>Heterozygous model</b>	25	63
<b>Dominant model</b>	5	73
<b>Allelic model</b>	8	0
<i>By polymorphism type</i>		
<b>rs4149056</b>	42	65
<b>rs2306283</b>	14	35
<b>rs4363657</b>	6	0
<i>rs4149056 by statin type</i>		
<b>Simvastatin</b>	13	79
<b>Atorvastatin</b>	11	0
<b>Rosuvastatin</b>	5	76
<b>Mixed statin</b>	11	60
<b>Cerivastatin</b>	1	NE
<b>Pravastatin</b>	1	NE
<i>rs4149056 by genetic model</i>		
<b>Heterozygous comparison</b>	17	69
<b>Homozygous comparison</b>	16	49
<b>Dominant model</b>	4	5
<b>Allelic model</b>	5	0

785 k: number of point estimates, I<sup>2</sup> : Proportion of heterogeneity (%), NA : not applicable, NE: not  
 786 executed

787

788 *Supplementary 8 (S8): Funnel plots of rs4149056 by type of statin*




789

790 Funnel plots of the association between, A [rs4149056– Simvastatin – SAMS k = 13], B [rs4149056–  
791 Atorvastatin – SAMS k = 11], C [rs4149056– Rosuvastatin – SAMS k = 5], D [rs4149056– mixed statin  
792 – SAMS k = 11]. k: number of point estimates. In the funnel plots each point is an estimation of the  
793 associations. The white, dark and light grey zones stand for a p value of the odds ratio i) non-significant,  
794 ii) between 0.05 and 0.01, and iii) <0.01, respectively. The dashed triangle stands for the estimation of  
795 the meta-analysis of the association, without adjusting for a potential publication bias.

796

797 *Supplementary 9 (S9): Funnel plot of rs4149056 by type of genetic model*



798

799 Funnel plot of the association between, A [rs4149056 Heterozygous comparison – Statin – SAMS k =  
 800 17], B [rs4149056 Homozygous comparison – Statin – SAMS k = 16], C [rs4149056 Dominant model  
 801 – Statin – SAMS k = 5], D [rs4149056 Allelic model – Statin – SAMS k = 5]. k: number of point  
 802 estimates. In the funnel plots each point is an estimation of the associations. The white, dark and light  
 803 grey zones stand for a p value of the odds ratio i) non-significant, ii) between 0.05 and 0.01, and iii)  
 804 <0.01, respectively. The dashed triangle stands for the estimation of the meta-analysis of the association,  
 805 without adjusting for a potential publication bias.

806 *Supplementary material 10 (S10) : Table of supplementary results for secondary analysis focused on rs4149056*

Association	k	Evaluation of publication bias			OR <sub>Uncorrected</sub> CI95%	OR <sub>Corrected</sub> CI95%		Effect of publication bias	
		Funnel plot	Egger	RoBMA		OR <sub>Trim&amp;Fill</sub>	OR <sub>RoBMA</sub>	ROR <sub>T&amp;F</sub> 95%CI	ROR <sub>RoBMA</sub> 95%CI
<b>rs4149056</b>	42	suggestive of a publication bias	0.001 *	In favor +	1.63 [1.34 - 1.99]	1.23 [0.96 - 1.58]	1.11 [1.00 - 1.77]	0.76 [0.55 - 1.04]	0.68 [0.55 - 0.86]
<i>By statin type</i>									
<b>Simvastatin</b>	13	suggestive of a publication bias	0,02 *	In favor	2.05 [1.24 - 3.41]	1.04 [0.55 - 1.96]	1.27 [0.98 - 2.75]	0.50 [0.22 - 1.14]	0.62 [0.35 - 1.10]
<b>Atorvastatin</b>	11	suggestive of a publication bias	0,1	NE	1.41 [1.09 - 1.84]	NE			
<b>Rosuvastatin</b>	5	undeterminable	NA	NE	1.62 [0.96 - 2.76]				
<b>Mixed statin</b>	11	suggestive of a publication bias	0,1	NE	1.47 [1.03 - 2.11]				
<b>Cerivastatin</b>	1	NA							
<b>Pravastatin</b>	1								
<i>By genetic model</i>									
<b>Heterozygous comparison</b>	17	suggestive of a publication bias	0,02 *	In favor +	1.37 [1.03 - 1.83]	1.04 [0.75 - 1.44]	1.03 [0.94 - 1.49]	0.75 [0.49 - 1.17]	0.75 [0.56 - 1.01]
<b>Homozygous comparison</b>	16	suggestive of a publication bias	0,1	NE	2.35 [1.46 - 3.76]	NE			
<b>Dominant model</b>	4	undeterminable	NA	NE	1.53 [0.93 - 2.50]				
<b>Allelic model</b>	5	undeterminable	NA	NE	1.82 [1.47 - 2.26]				


807 k: number of point estimates, \* indicates significant p-value, NA: not applicable, NE: not executed, because of non-significant Egger's test, +++

808 indicates Bayes factor <10, ++ indicates Bayes factor 3-10, + indicates Bayes factor <3, ROR<sub>Trim&Fill</sub>: ratio of OR<sub>Trim&Fill</sub> and OR<sub>Uncorrected</sub>;

809 ROR<sub>RoBMA</sub>: ratio of OR<sub>Robust Bayesian Meta-Analysis</sub> and OR<sub>Uncorrected</sub>




810 *Supplementary material 11 (S11): Funnel plot of the primary analysis [SLCO1B1 SNPs –*  
811 *Statins – SAMS] based on statin type*



812

813 **Figure S11: Funnel plot of the primary analysis [SLCO1B1 SNPs – Statins – SAMS k =**  
814 **62] based on statin type** - k: number of point estimates. In the funnel plots each point is an estimation  
815 of the associations, color corresponds to statin type. The white, dark and light grey zones stand for a p  
816 value of the odds ratio i) non-significant, ii) between 0.05 and 0.01, and iii)  $< 0.01$ , respectively. The  
817 dashed triangle stands for the estimation of the meta-analysis of the association, without adjusting for a  
818 potential publication bias.

819 *Supplementary material 12 (S12): Funnel plot of the association [SLCO1B1 SNPs –*  
820 *Statins – SAMS] based on study funding*




821

822 **Figure S12 Funnel plot of the association [SLCO1B1 SNPs – Statins – SAMS k = 62]**  
823 **based on sponsor type** - k: number of point estimates. In the funnel plots each point is an  
824 estimation of the associations, color corresponds to sponsor type. The white, dark and light grey zones  
825 stand for a p value of the odds ratio i) non-significant, ii) between 0.05 and 0.01, and iii) <0.01,  
826 respectively. The dashed triangle stands for the estimation of the meta-analysis of the association,  
827 without adjusting for a potential publication bias

828

829 *Supplementary material 13 (S13): Funnel plot of the association [SLCO1B1 SNPs –*  
830 *Statins – SAMS] based on ethnic group as reported in systematic reviews*



831

832 **Figure S13 Funnel plot of the association [SLCO1B1 SNPs – Statins – SAMS k = 62] based**  
833 **on ethnic group as reported in clinical studies** - k: number of point estimates. In the funnel plots  
834 each point is an estimation of the associations, color corresponds to sponsor type. The white, dark and  
835 light grey zones stand for a p value of the odds ratio i) non-significant, ii) between 0.05 and 0.01, and  
836 iii) <0.01, respectively. The dashed triangle stands for the estimation of the meta-analysis of the  
837 association, without adjusting for a potential publication bias

838